{
    "2018-02-08": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Top Research Reports for Novartis, BP & Biogen",
                "features": {
                    "keywords": [
                        "Novartis",
                        "BP",
                        "Biogen",
                        "Research Reports"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "How Pfizer’s Business Segments Performed in 4Q17",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Business Segments",
                        "4Q17"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Pfizer Reports Revenue Growth in 4Q17",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Revenue Growth",
                        "4Q17"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Amgen’s Repatha and Blincyto: How They Did in 3Q17",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Repatha",
                        "Blincyto",
                        "3Q17"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Cosentyx",
                        "Label Expansion",
                        "Scalp Psoriasis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Imbruvica Leads in the Chronic Lymphocytic Leukemia Space",
                "features": {
                    "keywords": [
                        "Imbruvica",
                        "Chronic Lymphocytic Leukemia"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Breakthrough",
                        "Cost Controversy"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "The Swiss Stock Market Dropped To Its Lowest Level Since April",
                "features": {
                    "keywords": [
                        "Swiss Stock Market",
                        "Dropped",
                        "Lowest Level"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Glaxo's Key Drug Gains Time as FDA Denies Novartis Generic",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "Key Drug",
                        "FDA",
                        "Novartis",
                        "Generic"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed",
                "features": {
                    "keywords": [
                        "GSK",
                        "Advair",
                        "Novartis",
                        "Reprieve",
                        "Delayed"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-12",
                "original_text": "Novartis Gets FDA Approval For Cosentyx Label Update - Quick Facts",
                "features": {
                    "keywords": [
                        "Novartis",
                        "FDA",
                        "Cosentyx",
                        "Label Update"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}